{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T10:57:07Z","timestamp":1758279427378},"reference-count":37,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To estimate costs of illness in a cross-sectional cohort of patients with gout attending an outpatient rheumatology clinic, and to evaluate which factors contribute to higher costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Altogether, 126 patients with gout were clinically assessed. They completed a series of questionnaires. Health resource use was collected using a self-report questionnaire that was cross-checked with the electronic patient file. Productivity loss was assessed by the Work Productivity and Activity Impairment Questionnaire, addressing absenteeism and presenteeism. Resource use and productivity loss were valued by real costs, and annual costs per patient were calculated. Factors contributing to incurring costs above the median were explored using logistic univariable and multivariable regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Mean (median) annual direct costs of gout were \u20ac5647 (\u20ac1148) per patient. Total costs increased to \u20ac6914 (\u20ac1279) or \u20ac10,894 (\u20ac1840) per patient per year when adding cost for absenteeism or both absenteeism and presenteeism, respectively. Factors independently associated with high direct and high indirect costs were a positive history of cardiovascular disease, functional limitations, and female sex. In addition, pain, gout concerns, and unmet gout treatment needs were associated with high direct costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The direct and indirect costs-of-illness of gout are primarily associated with cardiovascular disease, functional limitations, and female sex.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.140679","type":"journal-article","created":{"date-parts":[[2014,11,16]],"date-time":"2014-11-16T01:32:02Z","timestamp":1416101522000},"page":"335-344","source":"Crossref","is-referenced-by-count":17,"title":["Cost of Illness and Determinants of Costs Among Patients with Gout"],"prefix":"10.3899","volume":"42","author":[{"given":"Bart","family":"Spaetgens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.A.","family":"Wijnands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"van Durme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjef","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2014,11,15]]},"reference":[{"key":"2018112909335588000_42.2.335.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076232"},{"key":"2018112909335588000_42.2.335.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30520"},{"key":"2018112909335588000_42.2.335.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60883-7"},{"key":"2018112909335588000_42.2.335.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.207"},{"key":"2018112909335588000_42.2.335.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes211"},{"key":"2018112909335588000_42.2.335.6","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.7.742"},{"key":"2018112909335588000_42.2.335.7","first-page":"1152","article-title":"Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia","volume":"31","author":"Lin","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909335588000_42.2.335.8","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.10.1104"},{"key":"2018112909335588000_42.2.335.9","first-page":"1882","article-title":"Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome","volume":"34","author":"Hjortnaes","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909335588000_42.2.335.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.136218"},{"key":"2018112909335588000_42.2.335.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7151.111"},{"key":"2018112909335588000_42.2.335.12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18553\/jmcp.2008.14.2.164","article-title":"Disease-related and all-cause health care costs of elderly patients with gout","volume":"14","author":"Wu","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"2018112909335588000_42.2.335.13","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X112606"},{"key":"2018112909335588000_42.2.335.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2012.06.014"},{"key":"2018112909335588000_42.2.335.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.01.020"},{"key":"2018112909335588000_42.2.335.16","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/rheumatology\/kes183","article-title":"Comparison of patient characteristics and gout-related healthcare resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks","volume":"11","author":"Saseen","year":"2012","journal-title":"Rheumatology"},{"key":"2018112909335588000_42.2.335.17","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903017966"},{"key":"2018112909335588000_42.2.335.18","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181945d2c"},{"key":"2018112909335588000_42.2.335.19","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2012.0057"},{"key":"2018112909335588000_42.2.335.20","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31820543c5"},{"key":"2018112909335588000_42.2.335.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.699579"},{"key":"2018112909335588000_42.2.335.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.059451"},{"key":"2018112909335588000_42.2.335.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080506"},{"key":"2018112909335588000_42.2.335.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket423"},{"key":"2018112909335588000_42.2.335.25","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"2018112909335588000_42.2.335.26","unstructured":"Hakkaart-van Roijen L Tan SS Bouwmans CAM . [Guideline for cost-of-illness study: methods and guideline-rates for economic evaluations in health care]. [Book in Dutch] Rotterdam: College voor Zorgverzekeringen; 2010."},{"key":"2018112909335588000_42.2.335.27","unstructured":"College voor Zorgverzekeringen. [Drug prescription costs by College voor Zorgverzekeringen]. [Internet. Accessed October 9, 2014. Website in Dutch]. Available from: www.medicijnkosten.nl."},{"key":"2018112909335588000_42.2.335.28","doi-asserted-by":"publisher","DOI":"10.1016\/0167-6296(94)00044-5"},{"key":"2018112909335588000_42.2.335.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00173.x"},{"issue":"Suppl 55","key":"2018112909335588000_42.2.335.30","first-page":"112","article-title":"The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis","volume":"4","author":"Boonen","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 55","key":"2018112909335588000_42.2.335.31","first-page":"118","article-title":"Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis","volume":"4","author":"Franke","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909335588000_42.2.335.32","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M"},{"key":"2018112909335588000_42.2.335.33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.8.837"},{"key":"2018112909335588000_42.2.335.34","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#"},{"key":"2018112909335588000_42.2.335.35","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/eurheartj\/ehi733","article-title":"Economic burden of cardiovascular diseases in the enlarged European Union","volume":"13","author":"Leal","year":"2006","journal-title":"Eur Heart J"},{"key":"2018112909335588000_42.2.335.36","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321001-00005"},{"key":"2018112909335588000_42.2.335.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2009.01303.x"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.140679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T15:31:51Z","timestamp":1650641511000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.140679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,15]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,1]]},"published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.3899\/jrheum.140679"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.140679","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,15]]}}}